{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T05:31:23Z","timestamp":1794547883110,"version":"4.9.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI158080"],"award-info":[{"award-number":["AI158080"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["BX002788"],"award-info":[{"award-number":["BX002788"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-60828-9","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T07:53:27Z","timestamp":1751356407000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Copy number flexibility facilitates heteroresistance to increasing antibiotic pressure and threatens the beta-lactam pipeline"],"prefix":"10.1038","volume":"16","author":[{"given":"Jacob E.","family":"Choby","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tugba","family":"Ozturk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carter N.","family":"Abbott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9907-0508","authenticated-orcid":false,"given":"Christina","family":"Nnabuife","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer M.","family":"Colquhoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah W.","family":"Satola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9674-6250","authenticated-orcid":false,"given":"Philip N.","family":"Rather","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5267-0001","authenticated-orcid":false,"given":"Timothy","family":"Palzkill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0980-7866","authenticated-orcid":false,"given":"David S.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"60828_CR1","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","volume":"399","author":"Antimicrobial Resistance Collaborators.","year":"2022","unstructured":"Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 399, 629\u2013655 (2022).","journal-title":"Lancet"},{"key":"60828_CR2","unstructured":"Review on Antimicrobial Resistance. Antimicrobial resistance: tackling a crisis for the health and wealth of nations. https:\/\/amr-review.org\/sites\/default\/files\/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdf (2014)."},{"key":"60828_CR3","unstructured":"Review on Antimicrobial Resistance. Securing new drugs for future generations: the pipeline of antibiotics. https:\/\/amr-review.org\/sites\/default\/files\/SECURING%20NEW%20DRUGS%20FOR%20FUTURE%20GENERATIONS%20FINAL%20WEB_0.pdf (2015)."},{"key":"60828_CR4","unstructured":"Centers for Disease Control and Prevention. Outpatient antibiotic prescriptions \u2014 United States, 2020. https:\/\/www.cdc.gov\/antibiotic-use\/data\/report-2020.html (2020)."},{"key":"60828_CR5","unstructured":"The Pew Charitable Trusts. Analysis shows continued deficiencies in antibiotic development since 2014. https:\/\/www.pewtrusts.org\/en\/research-and-analysis\/data-visualizations\/2019\/five-year-analysis-shows-continued-deficiencies-in-antibiotic-development (2019)."},{"key":"60828_CR6","doi-asserted-by":"publisher","first-page":"6605","DOI":"10.1128\/AAC.01165-15","volume":"59","author":"RM Humphries","year":"2015","unstructured":"Humphries, R. M. et al. First report of ceftazidime-avibactam resistance in a KPC-3-expressing Klebsiella pneumoniae isolate. Antimicrob. Agents Chemother. 59, 6605\u20136607 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"60828_CR7","unstructured":"Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States. https:\/\/www.cdc.gov\/antimicrobial-resistance\/data-research\/threats\/index.html (2019)."},{"key":"60828_CR8","doi-asserted-by":"publisher","first-page":"4384","DOI":"10.1128\/AAC.03098-15","volume":"60","author":"T Ito-Horiyama","year":"2016","unstructured":"Ito-Horiyama, T. et al. Stability of novel siderophore cephalosporin S-649266 against clinically relevant carbapenemases. Antimicrob. Agents Chemother. 60, 4384\u20134386 (2016).","journal-title":"Antimicrob. Agents Chemother."},{"key":"60828_CR9","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.ijantimicag.2018.11.005","volume":"52","author":"L Poirel","year":"2018","unstructured":"Poirel, L., Kieffer, N. & Nordmann, P. Stability of cefiderocol against clinically significant broad-spectrum oxacillinases. Int. J. Antimicrob. Agents 52, 866\u2013867 (2018).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"60828_CR10","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1093\/jac\/dky317","volume":"73","author":"A Ito","year":"2018","unstructured":"Ito, A. et al. Stability and low induction propensity of cefiderocol against chromosomal AmpC beta-lactamases of Pseudomonas aeruginosa and Enterobacter cloacae. J. Antimicrob. Chemother. 73, 3049\u20133052 (2018).","journal-title":"J. Antimicrob. Chemother."},{"key":"60828_CR11","doi-asserted-by":"publisher","unstructured":"Frohlich, C., Sorum, V., Tokuriki, N., Johnsen, P. J. & Samuelsen, O. Evolution of beta-lactamase-mediated cefiderocol resistance. J. Antimicrob. Chemother. https:\/\/doi.org\/10.1093\/jac\/dkac221 (2022).","DOI":"10.1093\/jac\/dkac221"},{"key":"60828_CR12","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s10096-021-04397-x","volume":"41","author":"L Poirel","year":"2022","unstructured":"Poirel, L., Sadek, M., Kusaksizoglu, A. & Nordmann, P. Co-resistance to ceftazidime-avibactam and cefiderocol in clinical isolates producing KPC variants. Eur. J. Clin. Microbiol. Infect. Dis. 41, 677\u2013680 (2022).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"60828_CR13","doi-asserted-by":"publisher","unstructured":"Hackel, M. A. et al. In vitro activity of the siderophore cephalosporin, cefiderocol, against a recent collection of clinically relevant Gram-Negative Bacilli from North America and Europe, including carbapenem-nonsusceptible isolates (SIDERO-WT-2014 Study). Antimicrob. Agents Chemother. https:\/\/doi.org\/10.1128\/AAC.00093-17 (2017).","DOI":"10.1128\/AAC.00093-17"},{"key":"60828_CR14","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ijantimicag.2018.10.007","volume":"53","author":"KM Kazmierczak","year":"2019","unstructured":"Kazmierczak, K. M. et al. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-beta-lactamase-producing isolates (SIDEROG-WT-2014 Study). Int. J. Antimicrob. Agents 53, 177\u2013184 (2019).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"60828_CR15","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.ijantimicag.2018.11.007","volume":"53","author":"JA Karlowsky","year":"2019","unstructured":"Karlowsky, J. A. et al. In vitro activity of cefiderocol, a siderophore cephalosporin, against Gram-negative bacilli isolated by clinical laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015. Int. J. Antimicrob. Agents 53, 456\u2013466 (2019).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"60828_CR16","doi-asserted-by":"publisher","unstructured":"Hackel, M. A. et al. In vitro activity of the siderophore cephalosporin, cefiderocol, against carbapenem-nonsusceptible and multidrug-resistant isolates of gram-negative bacilli collected worldwide in 2014 to 2016. Antimicrob. Agents Chemother. https:\/\/doi.org\/10.1128\/AAC.01968-17 (2018).","DOI":"10.1128\/AAC.01968-17"},{"key":"60828_CR17","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1128\/AAC.01695-15","volume":"60","author":"N Kohira","year":"2016","unstructured":"Kohira, N. et al. In vitro antimicrobial activity of a siderophore cephalosporin, S-649266, against enterobacteriaceae clinical isolates, including carbapenem-resistant strains. Antimicrob. Agents Chemother. 60, 729\u2013734 (2016).","journal-title":"Antimicrob. Agents Chemother."},{"key":"60828_CR18","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","volume":"21","author":"M Bassetti","year":"2021","unstructured":"Bassetti, M. et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect. Dis. 21, 226\u2013240 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"60828_CR19","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1038\/s41564-019-0480-z","volume":"4","author":"VI Band","year":"2019","unstructured":"Band, V. I. et al. Antibiotic combinations that exploit heteroresistance to multiple drugs effectively control infection. Nat. Microbiol. 4, 1627\u20131635 (2019).","journal-title":"Nat. Microbiol."},{"key":"60828_CR20","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41579-019-0218-1","volume":"17","author":"DI Andersson","year":"2019","unstructured":"Andersson, D. I., Nicoloff, H. & Hjort, K. Mechanisms and clinical relevance of bacterial heteroresistance. Nat. Rev. Microbiol. 17, 479\u2013496 (2019).","journal-title":"Nat. Rev. Microbiol."},{"key":"60828_CR21","doi-asserted-by":"publisher","unstructured":"Band, V. I. et al. Carbapenem-resistant Klebsiella pneumoniae exhibiting clinically undetected colistin heteroresistance leads to treatment failure in a murine model of infection. MBio https:\/\/doi.org\/10.1128\/mBio.02448-17 (2018).","DOI":"10.1128\/mBio.02448-17"},{"key":"60828_CR22","doi-asserted-by":"publisher","first-page":"16053","DOI":"10.1038\/nmicrobiol.2016.53","volume":"1","author":"VI Band","year":"2016","unstructured":"Band, V. I. et al. Antibiotic failure mediated by a resistant subpopulation in Enterobacter cloacae. Nat. Microbiol. 1, 16053 (2016).","journal-title":"Nat. Microbiol."},{"key":"60828_CR23","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S1473-3099(21)00194-8","volume":"21","author":"JE Choby","year":"2021","unstructured":"Choby, J. E., Ozturk, T., Satola, S. W., Jacob, J. T. & Weiss, D. S. Widespread cefiderocol heteroresistance in carbapenem-resistant Gram-negative pathogens. Lancet Infect. Dis. 21, 597\u2013598 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"60828_CR24","doi-asserted-by":"publisher","unstructured":"Choby, J. E., Ozturk, T., Satola, S. W., Jacob, J. T. & Weiss, D. S. Does cefiderocol heteroresistance explain the discrepancy between the APEKS-NP and CREDIBLE-CR clinical trial results? Lancet Microbe https:\/\/doi.org\/10.1016\/S2666-5247(21)00271-8 (2021).","DOI":"10.1016\/S2666-5247(21)00271-8"},{"key":"60828_CR25","doi-asserted-by":"publisher","first-page":"dlae146","DOI":"10.1093\/jacamr\/dlae146","volume":"6","author":"RK Shields","year":"2024","unstructured":"Shields, R. K. et al. Frequency of cefiderocol heteroresistance among patients treated with cefiderocol for carbapenem-resistant Acinetobacter baumannii infections. JAC Antimicrob. Resist. 6, dlae146 (2024).","journal-title":"JAC Antimicrob. Resist."},{"key":"60828_CR26","unstructured":"Clinical and Laboratory Standards Institute. In CLSI M100-ED35:2025 Performance Standards for Antimicrobial Susceptibility Testing, 35th edn (Clinical and Laboratory Standards Institute, 2025)."},{"key":"60828_CR27","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/nrmicro.2016.34","volume":"14","author":"A Brauner","year":"2016","unstructured":"Brauner, A., Fridman, O., Gefen, O. & Balaban, N. Q. Distinguishing between resistance, tolerance and persistence to antibiotic treatment. Nat. Rev. Microbiol. 14, 320\u2013330 (2016).","journal-title":"Nat. Rev. Microbiol."},{"key":"60828_CR28","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1146\/annurev-genet-102108-134805","volume":"43","author":"DI Andersson","year":"2009","unstructured":"Andersson, D. I. & Hughes, D. Gene amplification and adaptive evolution in bacteria. Annu. Rev. Genet. 43, 167\u2013195 (2009).","journal-title":"Annu. Rev. Genet."},{"key":"60828_CR29","doi-asserted-by":"publisher","unstructured":"Ramarao, N., Nielsen-Leroux, C. & Lereclus, D. The insect Galleria mellonella as a powerful infection model to investigate bacterial pathogenesis. J. Vis. Exp. https:\/\/doi.org\/10.3791\/4392 (2012).","DOI":"10.3791\/4392"},{"key":"60828_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0147-619X(77)90003-8","volume":"1","author":"BE Uhlin","year":"1977","unstructured":"Uhlin, B. E. & Nordstrom, K. R plasmid gene dosage effects in Escherichia coli K-12: copy mutants of the R plasmic R1drd-19. Plasmid 1, 1\u20137 (1977).","journal-title":"Plasmid"},{"key":"60828_CR31","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1128\/AAC.42.5.1281","volume":"42","author":"P Giakkoupi","year":"1998","unstructured":"Giakkoupi, P. et al. Properties of mutant SHV-5 beta-lactamases constructed by substitution of isoleucine or valine for methionine at position 69. Antimicrob. Agents Chemother. 42, 1281\u20131283 (1998).","journal-title":"Antimicrob. Agents Chemother."},{"key":"60828_CR32","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.3389\/fmicb.2016.01374","volume":"7","author":"A Liakopoulos","year":"2016","unstructured":"Liakopoulos, A., Mevius, D. & Ceccarelli, D. A Review of SHV extended-spectrum beta-lactamases: neglected yet ubiquitous. Front. Microbiol. 7, 1374 (2016).","journal-title":"Front. Microbiol."},{"key":"60828_CR33","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1128\/AAC.33.6.951","volume":"33","author":"L Gutmann","year":"1989","unstructured":"Gutmann, L. et al. SHV-5, a novel SHV-type beta-lactamase that hydrolyzes broad-spectrum cephalosporins and monobactams. Antimicrob. Agents Chemother. 33, 951\u2013956 (1989).","journal-title":"Antimicrob. Agents Chemother."},{"key":"60828_CR34","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1093\/jac\/dkac197","volume":"77","author":"LS Witt","year":"2022","unstructured":"Witt, L. S. et al. Bacteraemia with an MBL-producing Klebsiella pneumoniae: treatment and the potential role of cefiderocol heteroresistance. J. Antimicrob. Chemother. 77, 2569\u20132571 (2022).","journal-title":"J. Antimicrob. Chemother."},{"key":"60828_CR35","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1073\/pnas.78.5.3113","volume":"78","author":"P Anderson","year":"1981","unstructured":"Anderson, P. & Roth, J. Spontaneous tandem genetic duplications in Salmonella typhimurium arise by unequal recombination between rRNA (rrn) cistrons. Proc. Natl. Acad. Sci. USA 78, 3113\u20133117 (1981).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"60828_CR36","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/s42003-021-02052-x","volume":"4","author":"C Pereira","year":"2021","unstructured":"Pereira, C., Larsson, J., Hjort, K., Elf, J. & Andersson, D. I. The highly dynamic nature of bacterial heteroresistance impairs its clinical detection. Commun. Biol. 4, 521 (2021).","journal-title":"Commun. Biol."},{"key":"60828_CR37","doi-asserted-by":"publisher","unstructured":"Anderson, S. E., Sherman, E. X., Weiss, D. S. & Rather, P. N. Aminoglycoside Heteroresistance in Acinetobacter baumannii AB5075. mSphere https:\/\/doi.org\/10.1128\/mSphere.00271-18 (2018).","DOI":"10.1128\/mSphere.00271-18"},{"key":"60828_CR38","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/s41564-018-0342-0","volume":"4","author":"H Nicoloff","year":"2019","unstructured":"Nicoloff, H., Hjort, K., Levin, B. R. & Andersson, D. I. The high prevalence of antibiotic heteroresistance in pathogenic bacteria is mainly caused by gene amplification. Nat. Microbiol. 4, 504\u2013514 (2019).","journal-title":"Nat. Microbiol."},{"key":"60828_CR39","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/mmi.13459","volume":"102","author":"K Hjort","year":"2016","unstructured":"Hjort, K., Nicoloff, H. & Andersson, D. I. Unstable tandem gene amplification generates heteroresistance (variation in resistance within a population) to colistin in Salmonella enterica. Mol. Microbiol. 102, 274\u2013289 (2016).","journal-title":"Mol. Microbiol."},{"key":"60828_CR40","doi-asserted-by":"publisher","unstructured":"Ozturk, T. & Weiss, D. S. Heteroresistance is a cause of discrepant antibiotic susceptibility testing results. Lancet Microbe https:\/\/doi.org\/10.1016\/S2666-5247(23)00374-9 (2024).","DOI":"10.1016\/S2666-5247(23)00374-9"},{"key":"60828_CR41","doi-asserted-by":"publisher","unstructured":"Simner, P. J. & Patel, R. Cefiderocol antimicrobial susceptibility testing considerations: the Achilles heel of the Trojan horse? J. Clin. Microbiol. https:\/\/doi.org\/10.1128\/JCM.00951-20 (2020).","DOI":"10.1128\/JCM.00951-20"},{"key":"60828_CR42","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1093\/cid\/ciab888","volume":"75","author":"PJ Simner","year":"2022","unstructured":"Simner, P. J. et al. Progressive development of cefiderocol resistance in Escherichia coli during therapy is associated with an increase in blaNDM-5 copy number and gene expression. Clin. Infect. Dis. 75, 47\u201354 (2022).","journal-title":"Clin. Infect. Dis."},{"key":"60828_CR43","doi-asserted-by":"publisher","unstructured":"Teran, N. et al. The emergence of cefiderocol resistance in Pseudomonas aeruginosa from a heteroresistant isolate during prolonged therapy. Antimicrob. Agents Chemother. https:\/\/doi.org\/10.1128\/aac.01009-23 (2023).","DOI":"10.1128\/aac.01009-23"},{"key":"60828_CR44","doi-asserted-by":"publisher","first-page":"W484","DOI":"10.1093\/nar\/gkad326","volume":"51","author":"JR Grant","year":"2023","unstructured":"Grant, J. R. et al. Proksee: in-depth characterization and visualization of bacterial genomes. Nucleic Acids Res. 51, W484\u2013W492 (2023).","journal-title":"Nucleic Acids Res."},{"key":"60828_CR45","doi-asserted-by":"publisher","first-page":"D690","DOI":"10.1093\/nar\/gkac920","volume":"51","author":"BP Alcock","year":"2023","unstructured":"Alcock, B. P. et al. CARD 2023: expanded curation, support for machine learning, and resistome prediction at the Comprehensive Antibiotic Resistance Database. Nucleic Acids Res. 51, D690\u2013D699 (2023).","journal-title":"Nucleic Acids Res."},{"key":"60828_CR46","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.diagmicrobio.2019.03.003","volume":"94","author":"MA Hackel","year":"2019","unstructured":"Hackel, M. A. et al. Reproducibility of broth microdilution MICs for the novel siderophore cephalosporin, cefiderocol, determined using iron-depleted cation-adjusted Mueller-Hinton broth. Diagn. Microbiol. Infect. Dis. 94, 321\u2013325 (2019).","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"60828_CR47","unstructured":"bcl2fastq: A proprietary Illumina software for the conversion of BCL files to basecalls. https:\/\/support.illumina.com\/sequencing\/sequencing_software\/bcl2fastq-conversion-software.html (2017)."},{"key":"60828_CR48","doi-asserted-by":"publisher","unstructured":"Li, H. Aligning sequence reads, clone sequences and assemblycontigs with BWA-MEM. Preprint at https:\/\/doi.org\/10.48550\/arXiv.1303.3997 (2013).","DOI":"10.48550\/arXiv.1303.3997"},{"key":"60828_CR49","unstructured":"Picard Markduplicates, http:\/\/broadinstitute.github.io\/picard\/command-line-overview.html#MarkDuplicates (2021)."},{"key":"60828_CR50","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1093\/bioinformatics\/btv070","volume":"31","author":"O Brynildsrud","year":"2015","unstructured":"Brynildsrud, O., Snipen, L. G. & Bohlin, J. CNOGpro: detection and quantification of CNVs in prokaryotic whole-genome sequencing data. Bioinformatics 31, 1708\u20131715 (2015).","journal-title":"Bioinformatics"},{"key":"60828_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2199-4-11","volume":"4","author":"KC Murphy","year":"2003","unstructured":"Murphy, K. C. & Campellone, K. G. Lambda Red-mediated recombinogenic engineering of enterohemorrhagic and enteropathogenic E. coli. BMC Mol. Biol. 4, 11 (2003).","journal-title":"BMC Mol. Biol."},{"key":"60828_CR52","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/0378-1119(95)00193-A","volume":"158","author":"PP Cherepanov","year":"1995","unstructured":"Cherepanov, P. P. & Wackernagel, W. Gene disruption in Escherichia coli: TcR and KmR cassettes with the option of Flp-catalyzed excision of the antibiotic-resistance determinant. Gene 158, 9\u201314 (1995).","journal-title":"Gene"},{"key":"60828_CR53","doi-asserted-by":"publisher","first-page":"e00990","DOI":"10.1128\/AEM.00990-19","volume":"85","author":"JE Lazarus","year":"2019","unstructured":"Lazarus, J. E. et al. A new suite of allelic-exchange vectors for the scarless modification of proteobacterial genomes. Appl. Environ. Microbiol. 85, e00990\u201300919 (2019).","journal-title":"Appl. Environ. Microbiol."},{"key":"60828_CR54","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1042\/bj2760269","volume":"276","author":"RP Ambler","year":"1991","unstructured":"Ambler, R. P. et al. A standard numbering scheme for the class A beta-lactamases. Biochem. J. 276, 269\u2013270 (1991).","journal-title":"Biochem. J."},{"key":"60828_CR55","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25, 402\u2013408 (2001).","journal-title":"Methods"},{"key":"60828_CR56","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/978-1-4939-9118-1_11","volume":"1946","author":"AT Tucker","year":"2019","unstructured":"Tucker, A. T., Powers, M. J., Trent, M. S. & Davies, B. W. RecET-mediated recombineering in Acinetobacter baumannii. Methods Mol. Biol. 1946, 107\u2013113 (2019).","journal-title":"Methods Mol. Biol."},{"key":"60828_CR57","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/nmeth765","volume":"2","author":"KH Choi","year":"2005","unstructured":"Choi, K. H. et al. A Tn7-based broad-range bacterial cloning and expression system. Nat. Methods 2, 443\u2013448 (2005).","journal-title":"Nat. Methods"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60828-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60828-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60828-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T07:53:30Z","timestamp":1751356410000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60828-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["60828"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-60828-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.06.07.494873","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"30 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5721"}}